| Christopher Sumrall, | |
|
2100 Highway 61 N, Vicksburg, MS 39183-8211 | |
| (601) 218-6136 | |
| Not Available |
| Full Name | Christopher Sumrall |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 9 Years |
| Location | 2100 Highway 61 N, Vicksburg, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124409339 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R876323 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Merit Health Wesley | Hattiesburg, MS | Hospital |
| Forrest General Hospital | Hattiesburg, MS | Hospital |
| Mississippi Baptist Medical Center | Jackson, MS | Hospital |
| St Vincent Hot Springs | Hot springs, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hattiesburg Clinic, Pa | 5193706794 | 489 |
| Lifelinc Anesthesia Pllc | 0941347447 | 144 |
| Perioperative Services Of Mississippi, Llc | 8921365255 | 93 |
| Youngs Professional Services Llc | 2163524992 | 239 |
News Archive
The Board of Directors of Patterson Companies, Inc., today declared the quarterly cash dividend of $0.16 per share. The dividend will be payable on January 24, 2014, to shareholders of record on January 10, 2014.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
A team of researchers at the Naval Medical Research Center, Silver Spring, USA, analyzed the risk of transmission of SARS-CoV-2 among marine recruits. Their study titled, "SARS-CoV-2 Transmission among Marine Recruits during Quarantine," was published in the latest issue of the New England Journal of Medicine.
A recent study by a University of Northern British Columbia-based scientist associated with the UBC Faculty of Medicine and UNBC's Northern Medical Program demonstrates that Canada's drinking-age laws have a significant effect on youth mortality.
› Verified 6 days ago
| Entity Name | Jackson Anesthesia Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780737577 PECOS PAC ID: 3870585904 Enrollment ID: O20040331000285 |
News Archive
The Board of Directors of Patterson Companies, Inc., today declared the quarterly cash dividend of $0.16 per share. The dividend will be payable on January 24, 2014, to shareholders of record on January 10, 2014.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
A team of researchers at the Naval Medical Research Center, Silver Spring, USA, analyzed the risk of transmission of SARS-CoV-2 among marine recruits. Their study titled, "SARS-CoV-2 Transmission among Marine Recruits during Quarantine," was published in the latest issue of the New England Journal of Medicine.
A recent study by a University of Northern British Columbia-based scientist associated with the UBC Faculty of Medicine and UNBC's Northern Medical Program demonstrates that Canada's drinking-age laws have a significant effect on youth mortality.
› Verified 6 days ago
| Entity Name | Hattiesburg Clinic Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740213446 PECOS PAC ID: 5193706794 Enrollment ID: O20040528000685 |
News Archive
The Board of Directors of Patterson Companies, Inc., today declared the quarterly cash dividend of $0.16 per share. The dividend will be payable on January 24, 2014, to shareholders of record on January 10, 2014.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
A team of researchers at the Naval Medical Research Center, Silver Spring, USA, analyzed the risk of transmission of SARS-CoV-2 among marine recruits. Their study titled, "SARS-CoV-2 Transmission among Marine Recruits during Quarantine," was published in the latest issue of the New England Journal of Medicine.
A recent study by a University of Northern British Columbia-based scientist associated with the UBC Faculty of Medicine and UNBC's Northern Medical Program demonstrates that Canada's drinking-age laws have a significant effect on youth mortality.
› Verified 6 days ago
| Entity Name | Lifelinc Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801021464 PECOS PAC ID: 0941347447 Enrollment ID: O20130522000277 |
News Archive
The Board of Directors of Patterson Companies, Inc., today declared the quarterly cash dividend of $0.16 per share. The dividend will be payable on January 24, 2014, to shareholders of record on January 10, 2014.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
A team of researchers at the Naval Medical Research Center, Silver Spring, USA, analyzed the risk of transmission of SARS-CoV-2 among marine recruits. Their study titled, "SARS-CoV-2 Transmission among Marine Recruits during Quarantine," was published in the latest issue of the New England Journal of Medicine.
A recent study by a University of Northern British Columbia-based scientist associated with the UBC Faculty of Medicine and UNBC's Northern Medical Program demonstrates that Canada's drinking-age laws have a significant effect on youth mortality.
› Verified 6 days ago
| Entity Name | Northstar Anesthesia Of Mississippi Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124415567 PECOS PAC ID: 1658682117 Enrollment ID: O20150624002329 |
News Archive
The Board of Directors of Patterson Companies, Inc., today declared the quarterly cash dividend of $0.16 per share. The dividend will be payable on January 24, 2014, to shareholders of record on January 10, 2014.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
A team of researchers at the Naval Medical Research Center, Silver Spring, USA, analyzed the risk of transmission of SARS-CoV-2 among marine recruits. Their study titled, "SARS-CoV-2 Transmission among Marine Recruits during Quarantine," was published in the latest issue of the New England Journal of Medicine.
A recent study by a University of Northern British Columbia-based scientist associated with the UBC Faculty of Medicine and UNBC's Northern Medical Program demonstrates that Canada's drinking-age laws have a significant effect on youth mortality.
› Verified 6 days ago
| Entity Name | Perioperative Services Of Mississippi, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881123123 PECOS PAC ID: 8921365255 Enrollment ID: O20171122000010 |
News Archive
The Board of Directors of Patterson Companies, Inc., today declared the quarterly cash dividend of $0.16 per share. The dividend will be payable on January 24, 2014, to shareholders of record on January 10, 2014.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
A team of researchers at the Naval Medical Research Center, Silver Spring, USA, analyzed the risk of transmission of SARS-CoV-2 among marine recruits. Their study titled, "SARS-CoV-2 Transmission among Marine Recruits during Quarantine," was published in the latest issue of the New England Journal of Medicine.
A recent study by a University of Northern British Columbia-based scientist associated with the UBC Faculty of Medicine and UNBC's Northern Medical Program demonstrates that Canada's drinking-age laws have a significant effect on youth mortality.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Sumrall, 135 Marion Dr., Clinton, MS 39056 Ph: () - | Christopher Sumrall, 2100 Highway 61 N, Vicksburg, MS 39183-8211 Ph: (601) 218-6136 |
News Archive
The Board of Directors of Patterson Companies, Inc., today declared the quarterly cash dividend of $0.16 per share. The dividend will be payable on January 24, 2014, to shareholders of record on January 10, 2014.
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.
A team of researchers at the Naval Medical Research Center, Silver Spring, USA, analyzed the risk of transmission of SARS-CoV-2 among marine recruits. Their study titled, "SARS-CoV-2 Transmission among Marine Recruits during Quarantine," was published in the latest issue of the New England Journal of Medicine.
A recent study by a University of Northern British Columbia-based scientist associated with the UBC Faculty of Medicine and UNBC's Northern Medical Program demonstrates that Canada's drinking-age laws have a significant effect on youth mortality.
› Verified 6 days ago
Mr. Michael J Mcreynolds, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-831-1146 | |
Richard M Stone Jr., CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-883-5000 | |
Melanie Joan Waldrop, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2100 Hwy 61n, River Region Medical Center, Vicksburg, MS 39183 Phone: 601-883-5000 | |
Mr. Channon Lee Pruitt, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-883-5000 | |
Mr. Michael Edward Killen, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-883-5707 | |
Jackie L Benson, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2100 Highway 61 N, Vicksburg, MS 39183 Phone: 601-883-5000 |